Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma
Authors:
- 2 June 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 103 (9) , 1200-1208
Abstract
Background Resection with curative intent has been shown to prolong survival of patients with locoregional pancreatic ductal adenocarcinoma (PDAC). However, up to 33 per cent of patients are deemed unresectable at exploratory laparotomy owing to unanticipated locally advanced or metastatic disease. In these patients, prophylactic double bypass (PDB) procedures have been considered the standard of care. The aim of this study was to compare PDB with exploratory laparotomy alone in terms of impact on postoperative course, chemotherapy and overall survival. Methods This retrospective observational cohort study (2004–2013) was conducted using a prospective institutional database. Patients with histologically confirmed, unresectable PDAC were included. Relationships between PDB procedures, exploratory laparotomy alone, postoperative chemotherapy and best supportive care were investigated by means of Cox regression. Overall survival was compared using Kaplan–Meier estimations and log rank test. Results Of 503 patients with PDAC scheduled for resection with curative intent, 104 were deemed unresectable at laparotomy (resection rate 79·3 per cent). Seventy-four patients underwent PDB procedures and 30 had exploratory laparotomy alone. PDB and exploratory laparotomy were similar in terms of perioperative mortality, initiation of chemotherapy and overall survival. Compared with best supportive care, postoperative chemotherapy prolonged survival (8·0 versus 14·4 months in locally advanced PDAC, P = 0·007; 2·3 versus 8·0 months in metastatic PDAC, P < 0·001). Patients undergoing chemotherapy following exploratory laparotomy alone had longer median overall survival than patients undergoing chemotherapy following PDB procedures (16·3 versus 10·3 months; P = 0·040). Conclusion Patients with pancreatic cancer deemed unresectable at laparotomy may derive survival benefit from subsequent chemotherapy as opposed to supportive care alone. At laparotomy, proceeding with a bypass procedure for prophylactic symptom control may be prognostically unfavourable.Keywords
This publication has 32 references indexed in Scilit:
- Palliative Surgical Management of Patients with Unresectable Pancreatic Adenocarcinoma: Trends and Lessons Learned from a Large, Single Institution ExperienceJournal of Gastrointestinal Surgery, 2011
- Incidence and Survival of Pancreatic Head and Body and Tail CancersPancreas, 2010
- Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative StudyAnnals of Surgical Oncology, 2010
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2009
- Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trialsBritish Journal of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The anatomic location of pancreatic cancer is a prognostic factor for survivalHPB, 2008
- Pancreatic carcinoma: Palliative surgical and endoscopic treatmentHPB, 2006
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass11No competing interests declared.Journal of the American College of Surgeons, 1999